Why Is Arcellx, Inc. Common Stock (ACLX) Stock Up 77.7% Today?

Arcellx, Inc. (ACLX) stock rocketed 77.7% to $113.92 in early trading, crushing through resistance after Gilead Sciences announced it would acquire the clinical-stage immunotherapy company. Volume exploded to 15.01M shares—16.9x the 30-day average of 888K—as traders repriced ACLX on the deal news. The stock opened at $64.11 yesterday and never looked back. Gilead's acquisition validates Arcellx's CAR-T cell therapy platform and answers a critical question many biotech investors have asked: why is ACLX stock up today? The answer is straightforward—Gilead just removed execution risk by bringing a deep-pocketed pharma partner onboard to commercialize next-gen myeloma immunotherapies.

What's Driving ACLX Stock Up Today

Gilead's acquisition of Arcellx represents a major de-risking event for shareholders. The deal brings Arcellx's lead candidate—a next-generation CAR-T cell therapy targeting multiple myeloma—into Gilead's established oncology infrastructure. Gilead already has a foothold in cell therapy through its Kite subsidiary, which commercializes CAR-T therapies. Adding Arcellx accelerates Gilead's pipeline in a high-growth segment: the CAR T-cell therapy market is projected to witness significant upsurge through 2034, driven by emerging therapies and rising myeloma incidence across major markets.

For Arcellx shareholders, the acquisition eliminates clinical development risk, manufacturing bottlenecks, and go-to-market uncertainty. Clinical-stage biotech companies like ACLX typically face a binary outcome: drug approval and commercialization, or failure. Gilead's backing removes that binary—myeloma is a $10B+ addressable market globally, and Gilead has the distribution to capture meaningful share. The deal also validates investor thesis around precision-driven cancer biotechs; DelveInsight research shows 180+ companies are actively developing CAR T-cell therapies, but Arcellx's platform caught Gilead's attention enough to trigger an acquisition.

Secondary drivers include broader momentum in blood cancer treatment markets. Recent data shows accelerated growth across major markets (US, EU5, Japan) amid rising incidence and breakthroughs in immunotherapy. Gilead's move signals confidence in category growth and competitive positioning. The biotech sector has also seen increased M&A activity around precision cancer therapies in recent months, setting positive sentiment for clinical-stage names with differentiated assets.

ACLX Stock Key Levels to Watch

ACLX broke critical resistance today. The stock traded in a day range of $113.80–$114.26 before settling near the top, indicating sustained buying pressure. This represents a clean breakout above historical resistance that would have existed around $60–$70 based on pre-deal trading patterns.

Support levels to monitor: $110 (today's psychological floor), $105 (early-day low in acquisition surge), and $95 (potential consolidation zone if profit-taking emerges). Resistance: $120 (psychological round number), $130 (15% above current price), and $150 (if institutional coverage kicks in post-acquisition).

Volume context is critical here. Today's 15.01M share turnover dwarfs the 30-day average of 888K shares. This suggests institutional participation, deal arbitrage (risk arbitrage funds betting on deal certainty), and retail FOMO. The 16.9x volume multiple is extreme—typical for M&A events with significant premium announcements. Watch for volume normalization tomorrow; if buying continues on elevated volume, conviction is building. If volume falls but price holds, it's a sign of institutional accumulation post-deal.

52-week context: ACLX has traded in a wide range typical of clinical-stage biotechs. Today's move to $113.92 likely represents a new 52-week high, given the acquisition premium baked into the price.

What Analysts Say About ACLX Stock

Pre-acquisition analyst coverage on ACLX was limited—clinical-stage biotechs with market caps under $1B often lack sell-side consensus. However, the acquisition by Gilead validates the bull thesis that ACLX's technology platform and pipeline had institutional-grade merit.

Post-announcement, sell-side coverage will likely initiate or update ratings. Expect analysts to frame ACLX within Gilead's oncology portfolio. Gilead trades at approximately 12.8x forward earnings (as of late Feb 2026), a reasonable multiple for a large-cap pharma with strong cash generation. The CAR-T segment—where Gilead already competes through Kite—commands premium multiples given high margins and recurring revenue potential.

Consensus likely to emerge: ACLX shareholders should accept the deal as a full-value exit. Clinical-stage biotechs like ACLX face 70%+ probability of failure; Gilead's acquisition converts that risk into commercial certainty. The market is pricing the deal at $113.92, implying investors believe Gilead's offer price was fair to generous. If deal certainty is high (no regulatory hurdles expected), ACLX could consolidate near current levels or drift slightly lower as deal arbitrage unwinds.

What's Next for Arcellx Stock

Near-term catalyst: Deal closing and regulatory approval. Most biotech M&A closes within 4–6 months post-announcement, assuming no competitive bidders emerge and regulators don't flag antitrust concerns (unlikely here, given ACLX's clinical stage and Gilead's smaller role in CAR-T relative to competitors). Timeline: Expect Gilead to file Hart-Scott-Rodino (HSR) documentation within weeks, with potential close by Q2 2026.

Bull case: If Gilead's integration strategy accelerates ACLX's lead program into Phase 2/3 trials faster than ACLX could alone, clinical readouts in 2027–2028 could drive significant value creation for Gilead shareholders. Multiple myeloma CAR-T efficacy data will be watched across the oncology community.

Bear case: If Gilead's internal priorities shift or manufacturing constraints emerge post-acquisition, ACLX's pipeline could face delays. Gilead has divested non-core assets before; clinical-stage programs face deprioritization if commercial returns look weak or competing therapies advance faster.

Critical next event: Gilead earnings call and deal commentary scheduled for late February 2026. Expect management to detail deal terms, integration timeline, and timeline to clinical readouts. This will determine if ACLX holds $113+ or faces profit-taking pullback.

Frequently Asked Questions

Why is ACLX stock up 77.7% today?

Gilead Sciences announced it would acquire Arcellx to accelerate next-generation CAR-T cell therapy development for multiple myeloma. The acquisition removes clinical development and commercialization risk for ACLX shareholders, justifying a significant premium to pre-deal trading levels. Volume hit 15M shares (16.9x average) as institutional investors repriced the stock on deal certainty.

Is ACLX stock a buy at $113.92?

This depends on deal certainty and risk tolerance. If Gilead's offer price is firm and deal closing is highly probable (no regulatory or financing risk), current levels represent fair value for an exit rather than a buy opportunity. New investors buying here assume deal closing risk; existing shareholders should evaluate tax consequences of tendering shares versus holding for potential special dividend.

What is ACLX stock price target post-acquisition?

ACLX will likely trade near deal offer price ($113.92 current level implies near-full valuation) with minor drift until close. Post-close, ACLX will be delisted and merged into Gilead, so traditional price targets become obsolete. Gilead itself trades around $145–$155 per share; the acquisition is accretive if CAR-T market growth materializes as expected.

What is Arcellx's lead drug candidate?

ACLX's pipeline focuses on next-generation CAR-T cell therapies for multiple myeloma, acute myeloid leukemia, and solid tumors. The multiple myeloma program is the lead asset Gilead is acquiring. CAR-T therapies are personalized immunotherapies that reprogram a patient's own immune cells to target cancer.

When will the Gilead-Arcellx deal close?

Gilead typically closes M&A within 4–6 months post-announcement. Expect regulatory filings in March 2026 and potential close by Q2 2026, assuming no competitive bidders or antitrust complications.

The Bottom Line

ACLX's 77.7% surge reflects validation of Arcellx's CAR-T platform and a full-value exit for shareholders. Gilead's acquisition removes execution risk and unlocks commercial potential in a growing myeloma therapy market. The deal exemplifies broader momentum in precision oncology M&A. For traders, key levels are $120 resistance and $105 support; deal closing risk is minimal. Gilead earnings on late February will provide deal detail and timeline guidance.